Your search returned 6 results.

Sort
Results
1.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27284114
Year: 2016
Citation:
  • Diabetes Care. 39(9):1579-86, 2016 Sep
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
2.
Implications of remote monitoring Technology in Optimizing Traditional Self-Monitoring of blood glucose in adults with T2DM in primary care. MedStar authors:
  • Magee, Michelle
  • Montero, Alex R
  • Nassar, Carine M
  • Youssef, Gretchen A
PMID:
  • 34758807
Year: 2021
Citation:
  • BMC Endocrine Disorders. 21(1):222, 2021 Nov 10.
Institution:
  • MedStar Diabetes Institute
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Gann K, Magee MF, Montero AR, Nassar CM, Toro-Tobon D, Youssef GA
3.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28386990
Year: 2017
Citation:
  • Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
4.
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
  • Aroda, Vanita R
PMID:
  • 26990378
Year: 2016
Citation:
  • Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
5.
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. MedStar authors:
  • Weissman, Neil J
PMID:
  • 30145941
Year: 2018
Citation:
  • New England Journal of Medicine. 379(12):1107-1117, 2018 09 20.
Institution:
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Bohula EA, Bonaca MP, Brown C, Budaj A, CAMELLIA-TIMI 61 Steering Committee and Investigators, Dhadda S, Fanola CL, Francis B, Garcia-Castillo A, Gupta M, Im K, Inzucchi SE, Keech AC, Kuder J, Leiter LA, McGuire DK, Miao W, Patel T, Perdomo C, Qamar A, Ruff CT, Sabatine MS, Scirica BM, Smith SR, Weissman NJ, White HD, Wiviott SD
6.
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28939018
Year: 2017
Citation:
  • Journal of Diabetes & its Complications. 31(12):1719-1727, 2017 Dec.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Gourgari E, Hassanzadeh H, Shoulson I, Wilhelm EE
Pages

Powered by Koha